GDM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- GDM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- GDM-1
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.658
- ALLOGRAFT_REJECTION+0.563
- INTERFERON_GAMMA_RESPONSE+0.452
- E2F_TARGETS+0.312
- MITOTIC_SPINDLE+0.283
- G2M_CHECKPOINT+0.280
- INFLAMMATORY_RESPONSE+0.181
- DNA_REPAIR+0.155
- HEME_METABOLISM+0.130
- IL6_JAK_STAT3_SIGNALING+0.125
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.584
- OXIDATIVE_PHOSPHORYLATION-0.471
- GLYCOLYSIS-0.426
- TNFA_SIGNALING_VIA_NFKB-0.422
- ANGIOGENESIS-0.390
- PROTEIN_SECRETION-0.372
- UNFOLDED_PROTEIN_RESPONSE-0.365
- HYPOXIA-0.360
- ESTROGEN_RESPONSE_EARLY-0.357
- MTORC1_SIGNALING-0.333
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | NALM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.856 |
| 2 | SRR5088834 | — | — | 0.853 |
| 3 | SRR5088892 | — | — | 0.847 |
| 4 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.835 |
| 5 | SRR5088835 | — | — | 0.827 |
| 6 | becdc4f8-3eee-4085-9046-31c7a059adff | — | — | 0.819 |
| 7 | TCGA-85-A4PA-01A-11R-A24Z-07 | — | cohortMD2 | 0.817 |
| 8 | HNT34_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.816 |
| 9 | GSM5359433 | — | — | 0.808 |
| 10 | SRR8613806 | — | D | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.658 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.563 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.452 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.312 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.283 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.181 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.155 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.125 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.063 | Inavolisib | — uncovered |
| COMPLEMENT | 0.045 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.016 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.016 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.011 | Idelalisib | — uncovered |